Genome Biologics
Genome Biologics
  • Home
  • Therapies
  • Technology
  • Publications
  • Press
  • Our team
  • Horizon 2020
  • Contact us
  • Mehr
    • Home
    • Therapies
    • Technology
    • Publications
    • Press
    • Our team
    • Horizon 2020
    • Contact us
  • Home
  • Therapies
  • Technology
  • Publications
  • Press
  • Our team
  • Horizon 2020
  • Contact us

Press Release

Genome Biologics wins €9.8M EIC Accelerator funding

Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programmes for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally.

Article

Genome Biologics - AstraZeneca Research Collaboration

Genome Biologics enters into a research collaboration and exclusive license option agreement with AstraZeneca to identify drivers of cardiac regeneration and recovery in Myocardial Infarction, Heart Failure and Cardiotoxicity

Article

Press

Research highlighted in Nature Reviews Cardiology

Article

Top 100 Fastest Growing German Startup

Article

Global Top 5 AI-Driven Drug Discovery Startup

Article

Top 10 AI and Drug Discovery Company in Europe

Article

Revolutionizing drug research with EU grants

Article

Awards

European Awards in Medicine 2021

Genome Biologics wins the 2021 European Awards in Medicine (Drug Development category) for developing therapies for Cardiovascular and Cardiometabolic disease.

Article

Genome Biologics joins BLUE KNIGHT™

Blue Knight is a joint initiative between Johnson & Johnson Innovation–JLABS and the Biomedical Advanced Research and Development Authority (BARDA, of the U.S. Department of Health and Human Services),  that aims to stimulate and accelerate innovation to improve global health security. Genome Biologics is one of seven companies from across the globe selected to join Blue Knight.

Article

Johnson & Johnson Innovations (JLABS) Resident

Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

Article

European Innovation Council

SME Instrument Phase 1 & 2 winner

Article

German Biotechnology Day

Johnson & Johnson Innovations challenge winner

Article

Merck Innovations

Venture Lounge winner

Article

Copyright © 2023 Genome Biologics – Alle Rechte vorbehalten.

  • Privacy Policy

This site uses cookies.

We use cookies to analyze website traffic and to optimize your user experience for this website. If you accept cookies, your data will be merged with that of other users.

ACCEPT